Clinical Trials for Recurrent Oropharyngeal Cancer
This article provides information about ongoing clinical trials for patients with recurrent oropharyngeal cancer. Currently, there is 1 active clinical trial exploring new treatment approaches that combine immunotherapy with chemotherapy and radiation therapy. The trial is being conducted in Germany and focuses on testing whether pembrolizumab, an immunotherapy drug, can improve survival outcomes when used in combination with re-radiochemotherapy.
Clinical trial locations
- Germany
Study on Pembrolizumab and Drug Combination for Patients with Recurrent Head and Neck Cancer
This clinical trial is investigating treatment options for patients whose head and neck cancer has returned to the same area after previous treatment. The study compares two different treatment approaches: one involves giving re-radiochemotherapy (a combination of radiation and chemotherapy) followed by pembrolizumab, while the other involves pembrolizumab with or without chemotherapy.
Main inclusion criteria:
- You must be at least 18 years old
- You must have locoregionally recurrent or a second primary head and neck squamous cell carcinoma that has been confirmed through tissue samples
- The tumor cannot be surgically removed, or surgery would cause significant functional problems, or you have chosen not to have surgery
- Your cancer must not have spread to distant parts of the body
- You must have adequate organ and bone marrow function, including hemoglobin levels of at least 9.0 g/dL, white blood cell count of at least 3,000 per mm3, and platelet count greater than 100,000 per mm3
- Your PD-L1 combined positive score must be 1 or more, which is a marker that helps predict response to immunotherapy
- You must have had previous radio(chemo)therapy of the neck, with at least 6 months since your last treatment
- If you are a woman of childbearing potential, you must have a negative pregnancy test within 72 hours before starting treatment and agree to use highly effective birth control during the study and for 120 days after the last dose
Main exclusion criteria:
- You cannot have other types of cancer besides locoregionally recurrent head and neck squamous cell carcinoma
- You cannot be pregnant or breastfeeding
- You cannot have severe or uncontrolled medical conditions that could interfere with the study
- You cannot have known allergies to the study medications
- You may not be eligible if you have participated in another clinical trial recently or have had a different type of cancer treatment recently
Focus and goal of the trial:
The main goal of this study is to determine whether the sequential treatment approach—giving re-radiochemotherapy followed by pembrolizumab—can improve overall survival compared to standard therapy. The trial will also assess how the treatment affects quality of life, swallowing function, and tumor symptoms. Participants will be randomly assigned to one of two treatment groups and will be monitored regularly through physical examinations, blood tests, imaging studies, and questionnaires throughout the study period.
Investigational drugs being tested:
The main investigational drug is pembrolizumab, an immunotherapy medication that works by helping the immune system recognize and attack cancer cells. It blocks a pathway that cancer cells use to hide from the immune system. Pembrolizumab is given as an intravenous infusion directly into the bloodstream.
In combination with pembrolizumab, the study also uses re-radiochemotherapy, which includes chemotherapy drugs such as fluorouracil, carboplatin, and cisplatin. These chemotherapy medications work to stop the growth of cancer cells and are administered alongside radiation therapy, which uses high-energy rays to target and destroy cancer cells.
Summary
Currently, there is one active clinical trial available for patients with recurrent oropharyngeal cancer, taking place in Germany. This trial focuses on evaluating whether combining immunotherapy with pembrolizumab and re-radiochemotherapy can improve survival outcomes for patients whose cancer has returned after initial treatment. The study represents an important effort to find more effective treatment approaches for this challenging condition, particularly for patients whose tumors cannot be surgically removed or who have chosen not to undergo surgery. The trial specifically targets patients whose tumors express PD-L1, a marker that may indicate better response to immunotherapy. Patients interested in participating should discuss eligibility requirements with their healthcare providers, particularly regarding previous treatment history and current health status.
